Evidence map›Paper›PMID 42639780›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026

Efficacy and safety of Heshu Xiaoji pills combined with standard treatment strategy in hepatitis B virus-related hepatocellular carcinoma: a single-center, open-label, prospective controlled, real-world cohort study.

Zhu Xiaoning, Yin Yue, Kong Yuan, Peng Mengyun, Peng Zhaoxuan, Zheng Ding, Wang Xiaodong, Han Yunwei, L I Bo, Liu Jurong and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Zhu XiaoningDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
Yin YueDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
Kong YuanSchool of Public Health, Center for Evidence-Based Medicine, Southwest Medical University, Luzhou646000, China.
Peng MengyunDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
Peng ZhaoxuanDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
Zheng DingDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
Wang XiaodongDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
Han YunweiSichuan Clinical Research Center for Traditional Chinese Medicine of Liver Diseases, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
L I BoDepartment of Hepatobiliary Surgery, the Affiliated Hospital, Southwest Medical University, Luzhou646000, China.
Liu JurongDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
Wang EnchengDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
Tian ZhenDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
Peng QinghuaDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
Jiang YuanyuanDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
M I ShaopingDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
Liu YongDepartment of Medical Imaging, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou646000, China.
P U QingrongInstitute of Pharmacy, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou646000, China.
Guo YongcanDepartment of Laboratory Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou646000, China.
H E QizhouDepartment of Medical Imaging, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou646000, China.
Cheng ChunxiaDepartment of Ultrasound, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou646000, China.
L I LinghuaDepartment of Electrocardiography, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou646000, China.
Jia HongSchool of Public Health, Center for Evidence-Based Medicine, Southwest Medical University, Luzhou646000, China.
Wang JingDepartment of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.

Funding

Natural Science Foundation of Sichuan Province-funded Project: Basic and Clinical Research on the Prevention and Treatment of Primary Liver Cancer Based on the Academic Thought of Professor Sun Tongjiao, a Nationally Renowned Traditional Chinese Medicine Practitioner 2022YFS0619Program of Southwest Medical University-funded Project: Mechanistic Study of Heshu Xiaoji Pills Targeting MicroRNAs to Regulate Cancer Stem Cells and Reduce Hepatocellular Carcinoma Recurrence 2023ZYYJ08Sichuan Science and Technology Program-funded Project: Evidence-based Research on Precision Treatment Strategies Using Traditional Chinese Medicine for Primary Liver Cancer 2024YFFK0086
6 · The paper itself

Abstract

objectiveTo evaluate the effectiveness and safety of Heshu Xiaoji pills (HSXJ, ) as an adjunct to standard treatment in patients with hepatitis B virus-related hepatocellular carcinoma.

methodsOverall, 201 patients enrolled between May 2020 and February 2022 received either HSXJ plus standard treatment (TCM group,

resultsBefore PSM, OS and PFS were significantly longer in the TCM group than in the Control group (OS: 609

conclusionsHSXJ combined with standard treatment strategy significantly improved PFS in patients with HBV-related HCC without added safety risks.

Indexed as

Carcinoma, HepatocellularDrugs, Chinese HerbalHepatitis BLiver NeoplasmsAdultAgedFemaleHepatitis B virusHumansMaleMiddle AgedProspective StudiesTreatment OutcomeDrugs, Chinese Herbalcarcinoma, hepatocellularchemotherapy, adjuvantHeshu Xiaoji pillsreal-world cohort study

Identifiers

PMID42639780
PMCPMC13494872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.